Financials in USD. Standardized financial statements.
A compact view of how Vivos Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $17.44M | $15.03M | $13.80M | $16.02M | $16.89M | $13.07M | $11.39M | $3.79M |
| Revenue Growth? | +16.0% | +8.9% | -13.9% | -5.1% | +29.2% | +14.7% | +200.4% | 0.0% |
| Cost of Revenue? | $6.90M | $6.01M | $5.53M | $6.00M | $4.28M | $2.65M | $2.74M | $1.08M |
| Gross Profit? | $10.54M | $9.02M | $8.27M | $10.02M | $12.60M | $10.41M | $8.66M | $2.71M |
| Gross Margin? | +60.4% | +60.0% | +59.9% | +62.5% | +74.6% | +79.7% | +76.0% | +71.5% |
| Operating Expenses? | $30.44M | $20.19M | $25.57M | $35.05M | $32.08M | $22.45M | $19.23M | $11.05M |
| Operating Income? | -$19.89M | -$11.17M | -$17.30M | -$25.03M | -$19.47M | -$12.04M | -$10.58M | -$8.34M |
| EBITDA? | -$18.59M | -$10.59M | -$16.68M | -$24.36M | -$19.54M | -$11.24M | -$9.87M | -$7.73M |
| Income Before Tax | -$21.23M | -$11.14M | -$13.58M | -$23.84M | -$20.29M | -$12.06M | -$10.75M | -$8.44M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$21.23M | -$11.14M | -$13.58M | -$23.84M | -$20.29M | -$12.06M | -$10.75M | -$8.44M |
| EPS? | $-2.06 | $-2.22 | $-11.14 | $-25.90 | $-23.89 | $-24.70 | $-21.94 | $-18.49 |
| Diluted EPS? | $-2.06 | $-2.22 | $-11.14 | $-25.90 | $-23.89 | $-24.70 | $-21.94 | $-18.49 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality